Suggested Readings

Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge.

Arbel R, Wolff Sagy Y, Hoshen M, et al. N Engl J Med. 2022;387(9):790-798.

Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.

Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.

End of the National Public Health Emergency for COVID-19: What Does It Mean for the Public?

Bonavitacola, J. Am J Manag Care. March 2, 2023.

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): Preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial

Butler C, Hobbs R, Gbinigie O, et al. SSRN. 2022. [Epub ahead of print].

Early remdesivir to prevent progression to severe Covid-19 in outpatients.

Gottlieb RL, Vaca CE, Paredes R, et al. N Engl J Med. 2022;386(4):305-315.

Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.

Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.

Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB.

Imai M, Ito M, Kiso M, et al. N Engl J Med. 2022. [Epub ahead of print]

Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.

Data and clinical considerations for additional doses in immunocompromised people.

Oliver S. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention; July 22, 2021.

Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.

Qu P, Evans JP, Faraone J, et al. bioRxiv. 2022:2022.2010.2019.512891.

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.

Wang Q, Iketani S, Li Z, et al. bioRxiv. 2022:2022.2011.2023.517532.

Improved neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent BA.4/5 vaccine.

Zou J, Kurhade C, Patel S, et al. bioRxiv. 2022:2022.2011.2017.516898.

Clinical Trials for investigational monoclonal antibodies

SUPERNOVA: AZD5156/AZD3152

ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05648110

VYD222

ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05791318

ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06039449

Related activities
Webcast 
1.00 CME/CE

What’s the Latest on COVID-19? - West Region

Current Prevention and Treatment Strategies

Faculty: Eric S. Daar, MD; Monica Gandhi, MD. MPH
Release: 11/28/2022
Expiration: 02/28/2023
Webcast 
1.00 CME/CE

What’s the Latest on COVID-19? - Midwest Region

Current Prevention and Treatment Strategies

Faculty: Daniel Kaul, MD; Raymund R. Razonable, MD, FIDSA, FAST
Release: 11/28/2022
Expiration: 02/28/2023
Webcast 
1.00 CME/CE

What’s the Latest on COVID-19? - South Region

Current Prevention and Treatment Strategies

Faculty: Roger J. Bedimo, MD; Leigh Lewis Speicher, MD, MPH
Release: 11/29/2022
Expiration: 03/01/2023
Webcast 
1.00 CME/CE

What’s the Latest on COVID-19? - Northeast Region

Current Prevention and Treatment Strategies

Faculty: Elizabeth P. Clayborne, MD, MA; Lewis W. Teperman, MD
Release: 12/08/2022
Expiration: 03/08/2023
 
0.25 CME/CE

Novel COVID-19 Subvariants and the Changing Treatment Landscape

A COVID-19 "Breaking News" Update

Faculty: Eric S. Daar, MD
Release: 12/23/2022
Expiration: 12/23/2023
 
0.25 CME/CE

Updates to Preventing and Treating COVID-19 in Immunocompromised Patients

Effect of XBB.1.5, BQ.1, and BQ.1.1 Subvariants

Faculty: Lewis W. Teperman, MD, FACS
Release: 01/27/2023
Expiration: 01/27/2024
 
0.25 CME/CE

Answers to Common Clinical Challenges in COVID-19

A COVID-19 "Breaking News" Update

Faculty: Elizabeth P. Clayborne, MD, MA
Release: 02/28/2023
Expiration: 02/28/2024
 
0.25 CME/CE

Anti-SARS-CoV-2 mAbs as Preexposure Prophylaxis

Proof of Concept and Future Directions

Faculty: Raymund R. Razonable, MD, FIDSA, FAST
Release: 03/10/2023
Expiration: 03/10/2024
 
0.25 CME/CE

The End of the COVID-19 Public Health Emergency

What Does This Mean for Your Practice?

Faculty: Leigh Lewis Speicher, MD, MPH
Release: 05/11/2023
Expiration: 05/11/2024
 
0.25 CME/AANP

The Latest Data in Anti-SARS-COV-2 Monoclonal Antibodies

A COVID-19 "Breaking News" Update

Faculty: Roger J. Bedimo, MD
Release: 02/15/2024
Expiration: 02/15/2025